Indication
Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).
Loading your page…
Loading your page…
Hepatitis C, Chronic
Marketing Authorisation Holder: Gilead Sciences Ireland UC
EMA Authorisation: 06/07/2016
INN: sofosbuvir;velpatasvir
AI Drug & Interaction Analysis
Free account required
Ask Osler about Epclusa: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.